Finally, following recent concerns by regulatory agencies regarding a potential increase in suicidal behavior associated with GLP-1RAs 206 , we found 1 recent pharmacovigilance report showing 0.6% suicidal events among 41,236 safety reports for these medications 207 and an emulated target trial of 86,418 older adults with T2DM that did not identify any difference in suicidal ideation or behavior between GLP-1RAs and other antidiabetic medications over 1.5 years 208
Because pediatric patients were never included in most clinical trials for these drugs, plaintiffs argue that prescribing them off-label created unacceptable dangers
These products reflect growing interest in food solutions that maintain strength and physiological balance
Are non-surgical options enough
According to clinical studies, 86% of subjects demonstrated improvement in wrinkle appearance
Proprietary data sets on adherence patterns, novel coaching methodologies, or predictive side-effect management can all serve as defensible IP